The four words every patient hopes to hear
You are in the recovery room, still groggy, and your family is gathered around the bed. The surgeon walks in, smiles, and says the words you have been praying for: “We got it all.” The room exhales. Someone cries. For the first time in weeks, you let yourself believe the nightmare is over.
I understand why those words are spoken, and I understand why they are so welcome. In most cases, the doctor who says them is being sincere and is reporting something real. The trouble is that the sentence promises far more than any surgeon, scan, or pathology report can know. It describes what could be seen and removed. It says nothing about what could not be seen, and in cancer, what cannot be seen is often what matters most over the years that follow.
You deserve to know what those four words really mean, what they leave out, and what you can do with the truth once you have it. None of this is meant to take away your hope. It is meant to put your hope on firmer ground.
What “we got it all” actually means
When a surgeon says the cancer is gone, the statement usually rests on three things. Everything that looked or felt like tumor was removed. The pathologist examined the edges of the removed tissue under a microscope and found no cancer cells at the border, which is called a clear or negative margin. The scans done before or after surgery also show no other tumors anywhere in your body.
All three are good news, and each one lowers the odds of cancer returning. But notice what they share. Every one of them depends on cancer being large enough to see. A surgeon’s eyes and hands find lumps, not single cells. A pathologist looks at thin slices of the specimen, not every cell, and cannot examine tissue that was never removed. A CT, MRI, or PET scan generally needs a deposit several millimeters across before anything shows up, and a deposit that size already contains millions of cells. A cluster of a few thousand cancer cells resting in your bone marrow, liver, or lung is invisible to all of them.
So the accurate translation of “we got it all” is this: “We removed all the cancer we were able to detect.” That is a meaningful accomplishment. It is not the same as saying no cancer cells remain, and no one could ever promise that.
The cells that left before the surgeon arrived
For much of the last century, cancer was pictured as a local problem that spread outward in an orderly way, first to nearby tissue, then to lymph nodes, and only late in the game to distant organs. If that picture were complete, cutting widely enough and early enough would cure nearly everyone. It is not complete. We now know that tumors can shed cells into the bloodstream and lymph long before anyone knows a tumor is there.
The clearest human evidence comes from breast cancer. In a pooled analysis published in the European Journal of Cancer, researchers gathered bone marrow results from 10,307 women with early breast cancer, sampled at the time of diagnosis before any treatment. Tumor cells were found in the bone marrow of 27.3%. These were women whose disease was considered early and operable, and more than one in four already had cancer cells living in their bones. Women with these cells had a 30% higher risk of relapse at distant sites and a 23% higher risk of death over the follow-up period.
Laboratory work points in the same direction. In a mouse model of breast cancer reported in Nature, cells that escaped from the earliest lesions went on to seed at least 80% of the eventual metastases. Mice are not people, but human data hint at something similar. A study in JAMA Oncology followed women diagnosed with ductal carcinoma in situ, the so-called stage 0 breast cancer that by definition has not invaded surrounding tissue. Twenty years later, 3.3% had died of breast cancer, and 517 of those women died without ever having an invasive cancer show up in the breast first. Something had left the breast before anyone thought it could.
These traveling cells do not always grow right away. Many settle into a quiet state called dormancy, where they sit for years without dividing. That is why cancer can return long after a patient has been told she is cured. A meta-analysis in the New England Journal of Medicine tracked 62,923 women with hormone-sensitive breast cancer who were free of disease after five years of endocrine therapy. Recurrences kept appearing at a steady pace from year 5 through year 20. Even among women with small tumors and no lymph node involvement, 13% developed distant metastases during those years, and for women with larger tumors and several positive nodes the figure climbed as high as 41%. Every one of those women had been disease-free on every available test for five full years.
Cancer stem cells: the seeds that can rebuild
Not every cancer cell is equally dangerous. Within many tumors, a small population of cells appears to have a special talent: they can renew themselves and regrow the whole tumor, much as healthy stem cells rebuild your gut lining or your blood. These are called cancer stem cells. In a widely cited review in Nature Medicine, Batlle and Clevers described how this idea helps explain some of the most frustrating facts in oncology, including why tumors so often come back after treatment that seemed to work, why cancer can lie dormant, and how metastases get started.
Cancer stem cells tend to divide slowly and to resist the stresses that kill ordinary tumor cells. Because chemotherapy and radiation hit fast-dividing cells hardest, treatment can shrink a tumor dramatically while leaving these hardier cells behind. The same review makes another point worth noting. “Stemness” is not always a fixed identity. Under the right signals from surrounding tissue, ordinary cancer cells can shift back into a stem-like state. In other words, the environment the cells live in helps decide how they behave.
Put the two ideas together and the weakness of “we got it all” becomes plain. If a handful of stem-like cells left the tumor months or years before surgery and are now resting somewhere else in the body, removing the original tumor does not touch them. The surgeon did the job well. The job simply had limits.
So is cancer local or systemic?
It would be easy to swing too far the other way and tell you that surgery never cures anyone. That would be just as misleading as “we got it all,” and I will not do it. Surgery cures a great many people, particularly when solid tumors are caught early.
Colon cancer gives us an honest look at the numbers. In a study published in Science Translational Medicine, researchers tested the blood of patients with stage II colon cancer after surgery for traces of tumor DNA, a sign that cancer cells remain somewhere in the body. Among 178 patients who received no chemotherapy, tumor DNA was found in 14, or 7.9%. Of those 14, 11 had relapsed by a median follow-up of 27 months, a rate of 79%. Among the 164 patients with no detectable tumor DNA, only 16, or 9.8%, relapsed. For most of these patients, the operation truly was enough.
Here is the lesson I take from that study. Every one of those 178 patients could have been told “we got it all,” and every one of them had the same clean margins and clean scans. Yet they were not in the same situation at all. Some were cured. Some still carried hidden disease and were headed for relapse. The four comforting words could not tell the two groups apart, and neither could the standard tests behind them.
A fair summary, then, is that cancer behaves as a whole-body disease far more often, and far earlier, than the phrase “we got it all” admits. How often depends on the type of cancer, its stage, and its biology. It is also worth remembering that most women in the bone marrow study who carried stray tumor cells did not relapse. Your body was designed with remarkable defenses, including an immune system that hunts abnormal cells and tissues that can hold dormant cells in check for a lifetime. Whether those cells stay asleep is not purely a matter of luck, and that is where you come in.
Why the phrase does real harm
If the words were merely imprecise, I would not be writing about them. The problem is what patients do after hearing them.
Some hear “we got it all” and decide that follow-up visits and scans are optional. Some decline or abandon the additional therapy their oncologist recommends, because why treat a disease that is gone? Many go straight back to the diet, the weight, the inactivity, the poor sleep, and the stress that formed the backdrop for the cancer in the first place. They were told the problem was gone, so they see no reason to change the conditions it grew in.
Then there is the emotional cost. When cancer returns in someone who believed she was cured, the recurrence feels like a betrayal. Patients in that position ask, “How can it be back? They told me they got it all.” Some blame themselves. Some lose trust in every doctor who treats them afterward. A more truthful conversation at the beginning would have spared them that particular wound, and might have given them years of purposeful action instead of false ease.
Better questions, and what to do with the answers
If you or someone you love has just heard “we got it all,” receive it as the good news it is, and then ask a few more questions. What were the margins, and how close was the closest one? Were lymph nodes removed, and how many held cancer? Given the type and stage of this cancer, what is the chance that cells have already traveled elsewhere? Is additional treatment recommended, and what is the follow-up schedule? A good surgeon or oncologist will welcome those questions.
Ask also whether a blood test for circulating tumor DNA makes sense in your case. These tests look for fragments of tumor DNA in the bloodstream after surgery, and they can reveal leftover disease that no scan can see. In the DYNAMIC trial, published in the New England Journal of Medicine, 455 patients with stage II colon cancer were assigned to have chemotherapy decisions guided either by this blood test or by standard criteria. The blood test group received chemotherapy about half as often (15% versus 28%), with no loss in two-year recurrence-free survival (93.5% versus 92.4%). Patients whose blood test was positive and who then received chemotherapy had a three-year recurrence-free survival of 86.4%, far better than the earlier study would have predicted for people in their situation left untreated. These tests are not available or validated for every cancer, and a negative result is not a guarantee, but they are the closest thing we have to an honest answer to the question “Did you really get it all?”
Then turn to what is in your own hands. The strongest proof that daily choices matter after surgery comes from the CHALLENGE trial, also in the New England Journal of Medicine. Researchers enrolled 889 patients who had finished surgery and chemotherapy for colon cancer and assigned half to a structured exercise program for three years. Five-year disease-free survival was 80.3% in the exercise group compared with 73.9% in the group that received health education materials alone. Eight-year overall survival was 90.3% versus 83.2%. Few drugs given after surgery can claim a benefit of that size, and this one came from walking shoes.
In our practice, we take the same view of the body’s internal environment. If dormant cells respond to their surroundings, then the surroundings deserve attention: blood sugar and insulin, chronic inflammation, body composition, nutrition, sleep, and stress. We measure what we can with comprehensive metabolic bloodwork, correct what we can, and repeat testing over time, because the months and years after surgery are not a finish line. They are a window of opportunity.
So when you hear “we got it all,” be thankful for a skilled surgeon and a successful operation. Then hear the fuller truth underneath it: the visible cancer is gone, and the work of keeping it gone now begins. You have been given a body with an extraordinary capacity to heal and defend itself. Caring for it faithfully from this day forward is not a sign of fear. It is good stewardship, and it is one of the most hopeful things you can do.

The question standard bloodwork never asks
Exercise is one way to change the environment that dormant cells live in. It is not the only one, and you cannot manage what you have never measured. This is where most follow-up care falls short.
After a successful operation, the typical patient gets a blood count, a basic chemistry panel, and perhaps a tumor marker every few months. Those tests have their place, but look at what they are designed to do. They ask one question: “Has a tumor come back?” They are a smoke detector. They tell you nothing until something is already burning, and a tumor marker that finally rises is reporting a recurrence that began long before.
The more useful question after “we got it all” is different: “What kind of environment are any remaining cells living in right now?” Earlier I described how cancer cells can shift into and out of a stem-like state depending on the signals around them, and how the body can hold stray cells in check for decades. Those signals travel through your blood. Insulin and blood sugar, markers of chronic inflammation, clotting tendency, nutrient status, hormone balance, and immune function all describe the terrain in which a dormant cell either stays asleep or wakes up. A standard oncology panel measures almost none of them.
That’s why we built the comprehensive panel described at CancerBloodwork.com. It looks at 35 biomarkers chosen to describe the whole metabolic and immune picture instead of a single tumor marker, and it turns a vague instruction like “live healthier” into specific targets you and your doctor can act on. Just as important, it gives you a baseline. Repeat the same panel over time, and you can see whether your efforts are moving the numbers; you may catch an unfavorable drift months before it shows up on a scan.
Let me be plain about what this testing does and does not do. It does not find hidden cancer cells, and no blood panel can promise that cancer will never return. It replaces false reassurance with real information. “We got it all” tells you about the tumor that was removed. Comprehensive bloodwork tells you about the body that remains, and that body will decide the rest of the story.
So when you hear “we got it all,” be thankful for a skilled surgeon and a successful operation. Then hear the fuller truth underneath it: the visible cancer is gone, and the work of keeping it gone now begins. Ask the better questions, get the comprehensive labs, and act on what they show. You have been given a body with an extraordinary capacity to heal and defend itself. Caring for it faithfully from this day forward is not a sign of fear. It is good stewardship, and it is one of the most hopeful things you can do.
References
- Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017 Oct 6;23(10):1124-1134.
- Courneya KS, Vardy JL, O’Callaghan CJ, Gill S, Friedenreich CM, Wong RKS, Dhillon HM, Coyle V, Chua NS, Jonker DJ, Beale PJ, Haider K, Tang PA, Bonaventura T, Wong R, Lim HJ, Burge ME, Hubay S, Sanatani M, Campbell KL, Arthuso FZ, Turner J, Meyer RM, Brundage M, O’Brien P, Tu D, Booth CM; CHALLENGE Investigators. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2025 Jul 3;393(1):13-25.
- Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Solà M, Walter V, Rack B, Schuetz F, Borgen E, Ta MH, Bittner AK, Fasching PA, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard FC, Kasimir-Bauer S, Schoenfisch B, Kurt AG, Wallwiener M, Gebauer G, Klein CA, Wallwiener D, Janni W, Pantel K. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. Eur J Cancer. 2021 Sep;154:128-137.
- Hosseini H, Obradović MMS, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, Nanduri LK, Werno C, Ehrl C, Maneck M, Patwary N, Haunschild G, Gužvić M, Reimelt C, Grauvogl M, Eichner N, Weber F, Hartkopf AD, Taran FA, Brucker SY, Fehm T, Rack B, Buchholz S, Spang R, Meister G, Aguirre-Ghiso JA, Klein CA. Early dissemination seeds metastasis in breast cancer. Nature. 2016 Dec 22;540(7634):552-558.
- Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol. 2015 Oct;1(7):888-96.
- Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017 Nov 9;377(19):1836-1846.
- Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, Khattak A, Burge M, Harris M, Lynam J, Nott L, Day F, Hayes T, McLachlan SA, Lee B, Ptak J, Silliman N, Dobbyn L, Popoli M, Hruban R, Lennon AM, Papadopoulos N, Kinzler KW, Vogelstein B, Tomasetti C, Gibbs P; DYNAMIC Investigators. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022 Jun 16;386(24):2261-2272.
- Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016 Jul 6;8(346):346ra92.
